TRCT
IBB icon

Tower Research Capital (TRC)’s iShares Biotechnology ETF IBB Stock Holding History

Tower Research Capital (TRC)’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.07M Buy
35,945
+17,217
+92% +$2.94M 0.16% 125
2025
Q4 		$3.16M Buy
18,728
+12,168
+185% +$1.98M 0.08% 225
2025
Q3 		$947K Sell
6,560
-44,477
-87% -$6.07M 0.03% 535
2025
Q2 		$6.46M Buy
51,037
+30,474
+148% +$3.74M 0.17% 97
2025
Q1 		$2.61M Buy
20,563
+20,557
+342,617% +$2.79M 0.08% 219
2024
Q4 		$793 Sell
6
-1,094
-99% -$154K ﹤0.01% 5167
2024
Q3 		$160K Buy
1,100
+941
+592% +$136K ﹤0.01% 1827
2024
Q2 		$21.8K Buy
159
+27
+20% +$3.6K ﹤0.01% 3707
2024
Q1 		$18.1K Buy
132
+57
+76% +$7.78K ﹤0.01% 3083
2023
Q4 		$10.2K Sell
75
-98,477
-100% -$12M ﹤0.01% 4281
2023
Q3 		$12.1M Buy
98,552
+98,203
+28,138% +$12.5M 0.38% 38
2023
Q2 		$44.3K Sell
349
-2,319
-87% -$301K ﹤0.01% 2671
2023
Q1 		$345K Sell
2,668
-17,233
-87% -$2.26M 0.01% 1057
2022
Q4 		$2.61M Sell
19,901
-78,476
-80% -$10.1M 0.11% 135
2022
Q3 		$11.5M Buy
98,377
+95,819
+3,746% +$11.9M 0.19% 92
2022
Q2 		$301K Sell
2,558
-6,390
-71% -$759K 0.01% 1478
2022
Q1 		$1.17M Sell
8,948
-17,979
-67% -$2.34M 0.01% 729
2021
Q4 		$4.11M Buy
26,927
+20,124
+296% +$3.12M 0.07% 233
2021
Q3 		$1.1M Sell
6,803
-5,896
-46% -$992K 0.03% 488
2021
Q2 		$2.08M Sell
12,699
-41,360
-77% -$6.37M 0.05% 293
2021
Q1 		$8.14M Buy
+54,059
New +$8.59M 0.14% 128
2020
Q4 		– Sell
-34,723
Closed -$4.7M – 5254
2020
Q3 		$4.7M Buy
+34,723
New +$4.71M 0.05% 89
2020
Q2 		– Sell
-186
Closed -$20K – 4848
2020
Q1 		$20K Sell
186
-54,432
-100% -$6.27M ﹤0.01% 1712
2019
Q4 		$6.58M Sell
54,618
-81,052
-60% -$9.04M 0.55% 17
2019
Q3 		$13.5M Buy
135,670
+135,513
+86,314% +$14.2M 0.93% 10
2019
Q2 		$17K Sell
157
-81
-34% -$8.62K ﹤0.01% 2273
2019
Q1 		$27K Sell
238
-91,218
-100% -$10M ﹤0.01% 2108
2018
Q4 		$8.82M Buy
91,456
+80,451
+731% +$8.54M 0.64% 20
2018
Q3 		$1.34M Buy
11,005
+10,997
+137,463% +$1.29M 0.1% 159
2018
Q2 		$1K Sell
8
-97
-92% -$10.4K ﹤0.01% 3481
2018
Q1 		$11K Sell
105
-18,513
-99% -$2.05M ﹤0.01% 2431
2017
Q4 		$1.99M Buy
18,618
+18,576
+44,229% +$1.99M 0.26% 75
2017
Q3 		$5K Sell
42
-41,058
-100% -$4.39M ﹤0.01% 3308
2017
Q2 		$4.25M Sell
41,100
-70,266
-63% -$6.92M 0.48% 31
2017
Q1 		$10.9M Sell
111,366
-930
-0.8% -$89K 1.09% 12
2016
Q4 		$9.93M Buy
+112,296
New +$10.2M 1.08% 5
2016
Q3 		– Sell
-311,910
Closed -$26.8M – 3985
2016
Q2 		$26.8M Buy
311,910
+172,230
+123% +$15.5M 2.56% 3
2016
Q1 		$12.1M Buy
+139,680
New +$12.5M 1.81% 6
2015
Q4 		– Sell
-4,938
Closed -$499K – 4715
2015
Q3 		$499K Buy
+4,938
New +$592K 0.05% 155
2015
Q1 		– Sell
-2,247
Closed -$227K – 4628
2014
Q4 		$227K Buy
+2,247
New +$218K 0.02% 271
2014
Q3 		– Sell
-20,370
Closed -$1.75M – 4609
2014
Q2 		$1.75M Buy
+20,370
New +$1.6M 0.22% 53
2013
Q4 		– Sell
-57,546
Closed -$4.02M – 4676
2013
Q3 		$4.02M Sell
57,546
-47,007
-45% -$3.08M 0.43% 41
2013
Q2 		$6.06M Buy
+104,553
New +$6.04M 0.49% 18

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Tower Research Capital (TRC)'s IBB Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its iShares Biotechnology ETF (IBB) stake by 92% in Q1 2026, buying an estimated $2.94M and bringing the position to 35,945 shares worth $6.07M. The position accounts for 0.16% of the portfolio, ranked #125.

Tower Research Capital (TRC) first reported a position in IBB in Q2 2013 and has held it in 43 quarters since. The position peaked at $26.8M in Q2 2016. 917 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

  • Tower Research Capital (TRC) held 35,945 shares of iShares Biotechnology ETF worth $6.07M as of Q1 2026.
  • Tower Research Capital (TRC) bought 17,217 iShares Biotechnology ETF shares in Q1 2026, an estimated $2.94M.
  • iShares Biotechnology ETF made up 0.16% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #125 holding.
  • Tower Research Capital (TRC) first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 43 quarters since.
  • Tower Research Capital (TRC)'s iShares Biotechnology ETF position peaked at $26.8M in Q2 2016.
  • 917 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.